Učitavanje...
Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy
Rucaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor and potent inhibitor of PARP1, PARP2 and PARP3 enzymes. Phase II and III trials have documented that rucaparib has single-agent antitumor activity in patients with high-grade ovarian carcinoma, with both BRCA-mutated (germline and somatic)...
Spremljeno u:
| Izdano u: | Ther Adv Med Oncol |
|---|---|
| Glavni autori: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
SAGE Publications
2018
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6024342/ https://ncbi.nlm.nih.gov/pubmed/29977351 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835918778483 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|